CN1961922A - Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof - Google Patents
Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof Download PDFInfo
- Publication number
- CN1961922A CN1961922A CN 200510115951 CN200510115951A CN1961922A CN 1961922 A CN1961922 A CN 1961922A CN 200510115951 CN200510115951 CN 200510115951 CN 200510115951 A CN200510115951 A CN 200510115951A CN 1961922 A CN1961922 A CN 1961922A
- Authority
- CN
- China
- Prior art keywords
- total
- radix astragali
- salviae miltiorrhizae
- extract
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 24
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 23
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 150000004676 glycans Chemical class 0.000 claims abstract description 82
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 82
- 239000005017 polysaccharide Substances 0.000 claims abstract description 82
- 229930182490 saponin Natural products 0.000 claims abstract description 82
- 150000007949 saponins Chemical class 0.000 claims abstract description 82
- 235000017709 saponins Nutrition 0.000 claims abstract description 82
- 239000000284 extract Substances 0.000 claims abstract description 46
- 238000002347 injection Methods 0.000 claims abstract description 40
- 239000007924 injection Substances 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 6
- 208000006011 Stroke Diseases 0.000 claims abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 3
- 201000011200 hepatorenal syndrome Diseases 0.000 claims abstract description 3
- 239000009636 Huang Qi Substances 0.000 claims description 95
- 150000007965 phenolic acids Chemical class 0.000 claims description 81
- 235000009048 phenolic acids Nutrition 0.000 claims description 81
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 claims description 62
- 241000208809 Carthamus Species 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- 239000000047 product Substances 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 32
- 241000628997 Flos Species 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 238000001556 precipitation Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- QWVMSYBGKWZIIE-RDFNRINOSA-N Flavochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CCCC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CCCC3(C)C)C QWVMSYBGKWZIIE-RDFNRINOSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- QWVMSYBGKWZIIE-FZKBJVJCSA-N flavochrome Chemical compound O1C2(C)CCCC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1C(C)=CCCC1(C)C QWVMSYBGKWZIIE-FZKBJVJCSA-N 0.000 claims description 12
- 239000008215 water for injection Substances 0.000 claims description 12
- 238000012856 packing Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 230000001476 alcoholic effect Effects 0.000 claims description 10
- 238000011067 equilibration Methods 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 239000002502 liposome Substances 0.000 claims description 10
- 238000007711 solidification Methods 0.000 claims description 10
- 230000008023 solidification Effects 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000000287 crude extract Substances 0.000 claims description 8
- 239000006196 drop Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000012869 ethanol precipitation Methods 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 8
- 238000007670 refining Methods 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000011664 nicotinic acid Substances 0.000 claims description 7
- 230000005496 eutectics Effects 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 210000004907 gland Anatomy 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 238000000859 sublimation Methods 0.000 claims description 5
- 230000008022 sublimation Effects 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 241001061264 Astragalus Species 0.000 claims description 4
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 claims description 4
- 240000007164 Salvia officinalis Species 0.000 claims description 4
- 235000006533 astragalus Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000007919 dispersible tablet Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 235000017276 Salvia Nutrition 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000001647 drug administration Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 235000005412 red sage Nutrition 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 229930189533 tanshinol Natural products 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 6
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 2
- 230000002490 cerebral effect Effects 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000945 filler Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 239000003350 kerosene Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003708 ampul Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- IOHZJWGBFQYXRW-GTDRIFFSSA-M sodium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol chloride Chemical compound [Na+].[Cl-].O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O IOHZJWGBFQYXRW-GTDRIFFSSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and use thereof, wherein the composition is prepared from one or more selected from total savianolic acid extract, astragalus root polysaccharides total saponins and carthamus tinctorius yellow color, various injection preparations and pharmacologically allowable dose forms such as oral administration preparations can be produced through charging auxiliary materials. The preparation of the composition is mainly used for treating ischemic cerebral apoplexy, angina pectoris caused by coronary disease, cardiac functional insufficiency, apoplexy after-effect, hepatorenal syndrome, coronary heart disease, diabetes and complications.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and its production and application, belong to technical field of medicaments.
Technical background
According to national health department's investigation statistics, 2004, ten thousand people died from cardiovascular and cerebrovascular disease surplus China had 260, and people's death was just arranged in average per 12 seconds, cardiovascular and cerebrovascular disease patient sum nearly 1.5 hundred million, and annual control expenditure surpasses 100,000,000,000.And the cardiovascular and cerebrovascular disease patient generally has hyperlipemia, hypertension, high blood viscosity, thrombosis, sclerosis of blood vessels, angiostenosis etc.If the Therapeutic Method of " medicine one is controlled, treated the head when the head aches, foot cure foot bitterly " according at present, so the patient must eat every day surplus " lipid lowerers, the depressor, fall the sticking medicine of blood, Pimobendane, thrombolytic medicine " etc. five, six kind even ten in the kind, Western medicine.Better prevent and treat purpose in order to reach, a large amount of research has been done by many inventors and medicine enterprise, and some outstanding treatment products also are provided; As: number of patent application is: 200410040197.8, name is called the patent application of " Chinese medicine preparation of treatment cardiovascular disease and preparation method thereof ", and the disease that it is used for the treatment for the treatment of cardiac and cerebral vascular diseases has definite curative effect; But in further investigation, find, adopt the effective site compatibility can not only reduce patient's dose, remove the strong composition of some toxic and side effects in the medicinal substances extract, the safety of preparation and the controllability of quality have been improved, greatly improve curative effect, and more help the molding of preparation, reduced some unnecessary technologies in the forming process.
Summary of the invention
The objective of the invention is to: a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and its production and application is provided; The present invention is directed to prior art, according to cardiovascular and cerebrovascular disease such as coronary heart disease, cerebral thrombosis, alzheimer disease etc. all contract because of blood vessel is narrow, reason such as blood flow minimizing causes the diseases induced principle of blood supply insufficiency, on the basis of experiment screening, adopt one or more compatibilities of Radix Salviae Miltiorrhizae total phenolic acids and Radix Astragali Mongolici total polysaccharide, total saponins and Flos Carthami flavochrome to make preparation, optimize best prescription and technology; The product that obtains, particularly ejection preparation product can play activating blood circulation to dissipate blood stasis, TONGMAI SHULUO, improve blood circulation and metabolism.For example coronary heart disease is that coronary atherosclerosis causes myocardial ischemia, anoxia and the heart disease that causes, and the said medicine compatibility can play and improve the myocardial metabolism effect, increases coronary flow, and the blood that improves cardiac muscle is provided with the effect of allevating angina pectoris.The present invention has curative effect preferably for treating cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, arrhythmia, cerebral thrombosis, alzheimer disease etc.But and the little patients life-time service of untoward reaction of the present invention.
The present invention constitutes like this: calculate according to percentage by weight, it is to be made one or more in X=Radix Astragali Mongolici total polysaccharide, the total saponins and Flos Carthami flavochrome by Radix Salviae Miltiorrhizae total phenolic acids 1～99% and X99～1% and suitable adjuvant.Be preferably: calculate according to percentage by weight, it is to be made one or more in X=Radix Astragali Mongolici total polysaccharide, the total saponins and Flos Carthami flavochrome by Radix Salviae Miltiorrhizae total phenolic acids 80～20% and X 20～80% and suitable adjuvant.Say accurately: calculate according to percentage by weight, it is to be made by Radix Salviae Miltiorrhizae total phenolic acids 60～40%, Radix Astragali Mongolici total polysaccharide, total saponins 30～40% and Carthamus yellow 10～20% and suitable adjuvant.Radix Salviae Miltiorrhizae total phenolic acids in the described prescription can be the highly finished product of tanshinol extract, Radix Salviae Miltiorrhizae water extract, Radix Salviae Miltiorrhizae water extract-alcohol precipitation extract, Radix Salviae Miltiorrhizae semi-bionic extraction thing, red sage root super critical extract or above each extract; Radix Astragali Mongolici total polysaccharide, total saponins can be the highly finished product of (+)-Astragenol extract, Radix Astragali water extract, Radix Astragali water extract-alcohol precipitation extract, Radix Astragali semi-bionic extraction thing, Radix Astragali supercritical extract or above each extract, and Carthamus yellow can be the highly finished product of Flos Carthami alcohol extract, Flos Carthami water extract, Flos Carthami water extract-alcohol precipitation extract, Flos Carthami semi-bionic extraction thing, Flos Carthami supercritical extract or above each extract.Described composite preparation be directly used in the injection of drug administration by injection, directly for the venous transfusion of intravenous drip, need be used for the concentrated solution for injection of intravenous drip and injectable sterile powder and aseptic block and tablet, capsule, granule, drop pill, pellet, pill, soft capsule, oral liquid, oral cavity disintegration tablet or the dispersible tablet that makes with freeze-drying or spray drying method after the dilution.Described preparation can make on the basis that in Radix Salviae Miltiorrhizae total phenolic acids and Radix Astragali Mongolici total polysaccharide, the total saponins and Flos Carthami flavochrome one or more is prepared into liposome or pro-liposome.Contain liposoluble ingredient, saponin component, polysaccharide composition and Flos Carthami flavochrome composition in the preparation, calculate by weight percentage, liposoluble ingredient content, saponin component content, polysaccharide component content and Carthamus yellow component content sum are not less than 50% of the total solid of deducting adjuvant amount and water quantities in the preparation in the preparation.Calculate according to percentage by weight, the content of liposoluble ingredient is not less than 50% in the Radix Salviae Miltiorrhizae total phenolic acids, and the content of polysaccharide composition is not less than 50% in the Radix Astragali Mongolici total polysaccharide, and the content of saponin component is not less than 50% in the Radix Astragali total saponins.
In the pharmaceutical composition of described treatment cardiovascular and cerebrovascular disease:
A, Carthamus yellow are preparations like this: get flos carthami, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Flos Carthami crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Carthamus yellow;
B, Radix Salviae Miltiorrhizae total phenolic acids effective site are preparations like this: get red rooted salvia, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Salviae Miltiorrhizae crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Salviae Miltiorrhizae total phenolic acids effective site;
C, Radix Astragali total saponins effective site are preparations like this: get Milkvetch Root, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate Radix Astragali crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Astragali total saponins effective site;
D, Radix Astragali Mongolici total polysaccharide effective site are preparations like this: get Milkvetch Root, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate Radix Astragali crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Astragali Mongolici total polysaccharide effective site.
The Injectable sterile block of described compositions prepares like this: get Radix Salviae Miltiorrhizae total phenolic acids and Carthamus yellow, Radix Astragali Mongolici total polysaccharide, one or more of total saponins, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.5～7.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-16 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2 hours approximately, keeps this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 10 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 9～11 hours, kept more than 35 ℃ dry 2.5 hours, gland, promptly.
Pro-liposome in the described preparation prepares like this: get one or more of Radix Salviae Miltiorrhizae total phenolic acids and Carthamus yellow, Radix Astragali Mongolici total polysaccharide, total saponins, add the phosphate buffer dissolving, add in the fused solution of fabaceous lecithin, cholesterol and 18-amine. mixing, stir, supersound process, freezing, the dry powder that obtains sieves, promptly.
Described compositions is mainly used in diseases such as treatment ischemia apoplexy, angina pectoris, cardiac insufficiency, apoplexy sequela, hepatorenal syndrome, heart and lung diseases, diabetes and complication thereof.
Compared with prior art, the applicant carried out lot of experiments, filtering out the prescription for the treatment of diseases such as angina pectoris is Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins and Flos Carthami flavochrome, and best compatibility scope is Radix Salviae Miltiorrhizae total phenolic acids 60～40%, Radix Astragali Mongolici total polysaccharide, total saponins 30～40% and Carthamus yellow 10～20%.Adopt good, the steady quality of prepared product appearance of the present invention.
For proving that medicine provided by the invention has effective effect, the applicant has carried out a series of experiments.
Experimental example 1: to the comparative study of different proportioning pharmacodynamics
We by antiplatelet aggregation test, suppress the mouse tail thrombotest, the prescription of different proportion has been carried out the screening test of system, wherein fill a prescription 1: model group gives normal saline; Prescription 2: Radix Salviae Miltiorrhizae total phenolic acids/Radix Astragali Mongolici total polysaccharide, Radix Astragali total saponins, Carthamus yellow=99/1; Prescription 3: Radix Salviae Miltiorrhizae total phenolic acids/Radix Astragali Mongolici total polysaccharide, Radix Astragali total saponins, Carthamus yellow=80/20; Prescription 4: Radix Salviae Miltiorrhizae total phenolic acids/Radix Astragali Mongolici total polysaccharide, total saponins/Carthamus yellow=60/30/10 group; Prescription 5: Radix Salviae Miltiorrhizae total phenolic acids/Radix Astragali Mongolici total polysaccharide, total saponins/Carthamus yellow=40/40/20; Prescription 6: Radix Salviae Miltiorrhizae total phenolic acids/Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow=20/80; Prescription 7: Radix Salviae Miltiorrhizae total phenolic acids/Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow=1/99, prescription 8: positive controls, the result is as follows:
The prescription research conclusion
| Formula number | The screening and assessment index | |
| Platelet suppression ratio (%) | Thrombosis suppression ratio (%) | |
| 1 2 3 4 5 6 7 8 | 0.24％ 44.5％ 49.2％ 56.3 57.1％ 47.7％ 42.9％ 55.8％ | -0.21％ 24.6％ 35.9％ 45.3％ 46.2％ 32.8％ 23.4％ 44.7％ |
By experimental result as can be known, Radix Salviae Miltiorrhizae total phenolic acids: Radix Astragali Mongolici total polysaccharide, total saponins: best compatibility scope=60～40%: 30～40% of Carthamus yellow: 10～20%.
Experimental example 2: injection Study on Forming
2.1 the selection of filler kind and consumption
The applicant finds that in development suitable filler, filler loading are powder injection formulation molding and stable key factor, and in order to improve the quality of this powder injection formulation, at first, the applicant investigates the kind of filler.The results are shown in following table.
Different filler kind screenings
| Filler | Mannitol | Glucose | Lactose | Sodium chloride | HP-β-CD |
| Medicine: adjuvant mouldability | 1: 2 good | Not molding in 1: 2 | Not molding in 1: 2 | Not molding in 1: 2 | Not molding in 1: 2 |
As seen, because the eutectic point height of mannitol, good water solubility be beneficial to the lyophilizing and the molding of this product, and other filler all is not suitable for this product, so selection mannitol is filler.
Then, the weight ratio of mannitol and effective ingredient is investigated, be the results are shown in following table.
The screening of mannitol consumption
| Medicine: mannitol | Color | Mouldability | Water solublity | Clarity |
| 1∶1.6 1∶2.0 1∶2.4 1∶2.8 | Yellow faint yellow yellowish white | Difference is good carefully | Difference is good carefully | The difference good job is poor |
As seen, medicine: mannitol=1: 2 o'clock, formed product is effective, considers from economic angle, determines medicine: mannitol=1: 2.
Experimental example 3: preparation pharmacodynamic experiment
Protective effect to Acute Myocardial Ischemia in Rats: get the SD rat; body weight 230～250g; male and female half and half; be divided into model group (giving the equivalent normal saline every day), oral liquid group of the present invention (administration every day 60mg/kg), injection group of the present invention (administration every day 60mg/kg), liposome group of the present invention (administration every day 60mg/kg) and Radix Salviae Miltiorrhizae/Radix Astragali/Flos Carthami 40/40/20 medical material proportioning injection group at random and (be called for short medical material compatibility group; administration every day 60mg/kg); every group 10; continuous 7 days, 1h ligation rat coronary artery left anterior descending branch after the last administration.Ventricle is got blood 3ml behind coronary ligation 3h, and centrifugal 5min prepares serum with the speed of 3000 * g, gets serum, measures corresponding index in the serum respectively with superoxide dismutase (SOD), malonaldehyde (MDA) test kit.Win rat heart and discharge hematocele in the chambers of the heart, inhale the branch that anhydrates, reject non-cardiac muscular tissues such as fatty blood vessel, wipe out atrium and right ventricle, stay left ventricle and weigh, calculate infarcted region (weight in wet base) and account for left ventricle (weight in wet base) percentage ratio with normal saline flushing and with filter paper.The results are shown in following table.
Influence to SOD, MDA in myocardial infarct size and the serum behind the rat coronary ligation
| Group | Heart infarction scope (%) | SOD(NU/ml) | MDA(nmol/ml) |
| Model group injection group of the present invention oral liquid group of the present invention lipidosome injection group of the present invention medical material compatibility group | 25.3±3.2 17.6±0.9 18.2±2.3 12.6±1.8 19.4±1.4 | 168.4±36.5 312.5±34.3 271.6±29.6 349.35±47.9 259.3±37.8 | 10.83±1.72 6.52±1.53 6.97±0.86 5.32±1.76 7.28±0.91 |
By experimental result as can be known, pharmaceutical preparation of the present invention can obviously improve SOD activity in the coronary ligation rat blood serum, has significantly suppressed the generation of MDA, and obviously reduces myocardial infarction district area, and lipidosome injection group curative effect of the present invention is significantly better than other each experimental grouies.
Concrete embodiment
Embodiments of the invention 1: Radix Salviae Miltiorrhizae total phenolic acids 60g Radix Astragali Mongolici total polysaccharide, total saponins 30g Carthamus yellow 10g
Get Radix Salviae Miltiorrhizae total phenolic acids, Carthamus yellow, Radix Astragali Mongolici total polysaccharide, total saponins, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.5～7.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-16 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2 hours approximately, keeps this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature, slowly heat up, 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 10 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 9～11 hours, kept more than 35 ℃ dry 2.5 hours, gland promptly gets the Injectable sterile block, one time 2,1 time on the one, with using behind the 250ml0.9% physiological saline solution.Calculate by weight percentage, in the injection polysaccharide component content, saponin component content, liposoluble ingredient content and carthamus tinctorius yellow color content sum be deduct in the preparation adjuvant amount and water quantities total solid 82%.
Embodiments of the invention 2: Radix Salviae Miltiorrhizae total phenolic acids 40g Radix Astragali Mongolici total polysaccharide, total saponins 40g Carthamus yellow 20g
Get Radix Salviae Miltiorrhizae total phenolic acids, Carthamus yellow, Radix Astragali Mongolici total polysaccharide, total saponins, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.5～7.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-16 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2 hours approximately, keeps this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 10 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 9～11 hours, kept more than 35 ℃ dry 2.5 hours, gland promptly gets the Injectable sterile block.
Embodiments of the invention 3: Radix Salviae Miltiorrhizae total phenolic acids 50g Radix Astragali Mongolici total polysaccharide, total saponins 35g Carthamus yellow 15g
Get Radix Salviae Miltiorrhizae total phenolic acids, Carthamus yellow, Radix Astragali Mongolici total polysaccharide, total saponins, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.5～7.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-16 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2 hours approximately, keeps this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 10 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 9～11 hours, kept more than 35 ℃ dry 2.5 hours, gland promptly gets the Injectable sterile block.
Embodiments of the invention 4: Radix Salviae Miltiorrhizae total phenolic acids 60g Radix Astragali Mongolici total polysaccharide, total saponins 30g Carthamus yellow 10g
Get Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow, add an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.0～6.5, boils, 4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add the injection water, divide to install to ampoule bottle, seal sterilization, promptly get injection with small volume or concentrated solution for injection.
Embodiments of the invention 5: Radix Salviae Miltiorrhizae total phenolic acids 40g Radix Astragali Mongolici total polysaccharide, total saponins 40g Carthamus yellow 20g
Get Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow, add an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.0～7.0, boils, 4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add the injection water, divide to install to ampoule bottle, seal sterilization, promptly get injection with small volume or concentrated solution for injection.
Embodiments of the invention 6: Radix Salviae Miltiorrhizae total phenolic acids 50g Radix Astragali Mongolici total polysaccharide, total saponins 35g Carthamus yellow 15g
Get Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow, add an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.0～7.0, boils, 4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add the injection water, divide to install to ampoule bottle, seal sterilization, promptly get injection and concentrated solution for injection.
Embodiments of the invention 7: Radix Salviae Miltiorrhizae total phenolic acids 80g Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow 20g
Get Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow, add an amount of water for injection dissolving, add the glucose or the sodium chloride of ormal weight, by volume add 0.5% active carbon behind the mixed dissolution, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, the saturated sodium hydroxide solution of reuse adjust pH to 6.0～7.0, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining add the injection water, packing, sterilization promptly gets glucose or sodium chloride intravenous infusion.
Embodiments of the invention 8: Radix Salviae Miltiorrhizae total phenolic acids 20g Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow 80g
Get Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow, add 5% sodium carboxymethyl cellulose and 1.2% mannitol, compacting promptly gets oral cavity disintegration tablet in flakes.
Embodiments of the invention 9: Radix Salviae Miltiorrhizae total phenolic acids 99g Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow 1g
With Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow mix homogeneously, to be that 1.2: 1 Macrogol 4000 is put in the rustless steel container with the principal agent ratio, add extract, mix homogeneously, be heated to 85-90 ℃, treat whole fusions after, 75-80 ℃ of insulation, mechanical high-speed stirs 15min to even, be transferred in the reservoir, the dropping liquid valve is regulated in 75～80 ℃ of insulations, splash in 35～40 ℃ the kerosene, drip apart from 5～6cm, drip 40～45 droplets/minute of speed, to the greatest extent and wipe kerosene the drop pill drop that forms, packing promptly gets drop pill.
Embodiments of the invention 10: Radix Salviae Miltiorrhizae total phenolic acids 1g Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow 99g
With Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow mix homogeneously, in principal agent: the ratio of adjuvant=1.1: 1 adds carboxymethyl starch, in principal agent: the ratio of adjuvant=1.5: 1 adds microcrystalline Cellulose, and press principal agent: the crospolyvinylpyrrolidone of adjuvant=4: 1, evenly mixed, make soft material in right amount with 75% ethanol, cross 20 mesh sieve system granules, 55 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets dispersible tablet.
Embodiments of the invention 11: Radix Salviae Miltiorrhizae total phenolic acids 95g Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow 5g
With Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow mix homogeneously, add 2 times of amount dextrin, 0.5% sucrose, 1.2% microcrystalline Cellulose with an amount of alcoholic solution system soft material, is granulated, and 60 ℃ of forced air dryings are granulated, and granulate promptly gets granule.
Embodiments of the invention 12: Radix Salviae Miltiorrhizae total phenolic acids 5g Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow 95g
With Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow mix homogeneously, add the starch of equivalent, mix homogeneously is granulated, and is encapsulated, promptly gets capsule.
Embodiments of the invention 13: Radix Salviae Miltiorrhizae total phenolic acids 85g Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow 15g
With Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow mix homogeneously, add distilled water, filter repeatedly, till the filtrate clarification., filter with absorbent cotton after the stirring and dissolving in filtrate with sucrose, it is an amount of to add distilled water on filter, shakes up, and promptly gets syrup.
Embodiments of the invention 14: Radix Salviae Miltiorrhizae total phenolic acids 15g Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow 85g
Get Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow, mixing adds an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.0～7.0, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining are 120 ℃ in inlet temperature, leaving air temp is 60 ℃, and air velocity is 20ms
1Condition under spray drying get powder, packing promptly gets injectable sterile powder.
Embodiments of the invention 15: Radix Salviae Miltiorrhizae total phenolic acids 80g Radix Astragali Mongolici total polysaccharide, total saponins 20g
Get Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, add an amount of water for injection dissolving, add the glucose or the sodium chloride of ormal weight, by volume add 0.5% active carbon behind the mixed dissolution, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, the saturated sodium hydroxide solution of reuse adjust pH to 6.0～7.0, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining add the injection water, packing, sterilization promptly gets glucose or sodium chloride intravenous infusion.
Embodiments of the invention 16: Radix Salviae Miltiorrhizae total phenolic acids 20g Radix Astragali Mongolici total polysaccharide, total saponins 80g
Get Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, add 5% sodium carboxymethyl cellulose and 1.2% mannitol, compacting promptly gets oral cavity disintegration tablet in flakes.
Embodiments of the invention 17: Radix Salviae Miltiorrhizae total phenolic acids 99g Radix Astragali Mongolici total polysaccharide, total saponins 1g
With Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins mix homogeneously, to be that 1.2: 1 Macrogol 4000 is put in the rustless steel container with the principal agent ratio, add extract, mix homogeneously, be heated to 85-90 ℃, treat whole fusions after, 75-80 ℃ of insulation, mechanical high-speed stirs 15min to even, be transferred in the reservoir, the dropping liquid valve is regulated in 75～80 ℃ of insulations, splash in 35～40 ℃ the kerosene, drip apart from 5～6cm, drip 40～45 droplets/minute of speed, to the greatest extent and wipe kerosene the drop pill drop that forms, packing promptly gets drop pill.
Embodiments of the invention 18: Radix Salviae Miltiorrhizae total phenolic acids 1g Radix Astragali Mongolici total polysaccharide, total saponins 99g
With Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins mix homogeneously, in principal agent: the ratio of adjuvant=1.1: 1 adds carboxymethyl starch, by principal agent: the ratio adding microcrystalline Cellulose of adjuvant=1.5: 1, and press principal agent: the crospolyvinylpyrrolidone of adjuvant=4: 1, evenly mixed, make soft material in right amount with 75% ethanol, cross 20 mesh sieve system granules, 55 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets dispersible tablet.
Embodiments of the invention 19: Radix Salviae Miltiorrhizae total phenolic acids 80g Carthamus yellow 20g
With Radix Salviae Miltiorrhizae total phenolic acids, Carthamus yellow mix homogeneously, add 2 times of amount dextrin, 0.5% sucrose, 1.2% microcrystalline Cellulose with an amount of alcoholic solution system soft material, is granulated, and 60 ℃ of forced air dryings are granulated, and granulate promptly gets granule.
Embodiments of the invention 20: Radix Salviae Miltiorrhizae total phenolic acids 20g Carthamus yellow 90g
With Radix Salviae Miltiorrhizae total phenolic acids, Carthamus yellow mix homogeneously, add the starch of equivalent, mix homogeneously is granulated, and is encapsulated, promptly gets capsule.
Embodiments of the invention 21: Radix Salviae Miltiorrhizae total phenolic acids 99g Carthamus yellow 1g
With Radix Salviae Miltiorrhizae total phenolic acids, Carthamus yellow mix homogeneously, add distilled water, filter repeatedly, till the filtrate clarification., filter with absorbent cotton after the stirring and dissolving in filtrate with sucrose, it is an amount of to add distilled water on filter, shakes up, and promptly gets syrup.
Embodiments of the invention 22: Radix Salviae Miltiorrhizae total phenolic acids 1g Carthamus yellow 99g
Get Radix Salviae Miltiorrhizae total phenolic acids, Carthamus yellow, mixing adds an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.0～6.5, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining are 120 ℃ in inlet temperature, leaving air temp is 60 ℃, and air velocity is 20ms
-1Condition under spray drying get powder, packing promptly gets injectable sterile powder.
Embodiments of the invention 23: Radix Salviae Miltiorrhizae total phenolic acids 40g Radix Astragali Mongolici total polysaccharide, total saponins 40g Carthamus yellow 20g
With Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins and Flos Carthami flavochrome mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 10min, gets liposome turbid liquor, the phosphate buffer standardize solution, filtration sterilization, aseptic subpackaged, promptly get lipidosome injection.
Embodiments of the invention 24: Radix Salviae Miltiorrhizae total phenolic acids 20g Radix Astragali Mongolici total polysaccharide, total saponins 40g Carthamus yellow 40g
With Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins and Flos Carthami flavochrome mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 8min, gets liposome turbid liquor, behind the frozen drying, cross 180 mesh sieves, aseptic subpackaged, promptly get the pro-liposome injectable powder.
Radix Salviae Miltiorrhizae total phenolic acids among the above embodiment, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellow can be with Radix Salviae Miltiorrhizae total phenolic acids, Radix Astragali Mongolici total polysaccharide, total saponins, Carthamus yellows commercially available or that make by the inventive method, no matter be alcohol extract, water extract, water extract-alcohol precipitation extract, semi-bionic extraction thing or supercritical extract etc., but, wherein total phenolic content of Radix Salviae Miltiorrhizae total phenolic acids is greater than 50%, the total polysaccharides content of Radix Astragali Mongolici total polysaccharide is greater than 50%, the total saponin content of Radix Astragali total saponins can guarantee the therapeutic effect of product like this greater than 50%.
Claims (12)
1, a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is characterized in that: calculate according to percentage by weight, it is to be made one or more in X=Radix Astragali Mongolici total polysaccharide, the total saponins and Flos Carthami flavochrome by Radix Salviae Miltiorrhizae total phenolic acids 1～99% and X 99～1% and suitable adjuvant.
2, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: calculate according to percentage by weight, it is to be made one or more in X=Radix Astragali Mongolici total polysaccharide, the total saponins and Flos Carthami flavochrome by Radix Salviae Miltiorrhizae total phenolic acids 80～20% and X 20～80% and suitable adjuvant.
3, according to the pharmaceutical composition of claim 1 or 2 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: calculate according to percentage by weight, it is to be made by Radix Salviae Miltiorrhizae total phenolic acids 60～40%, Radix Astragali Mongolici total polysaccharide, total saponins 30～40% and Carthamus yellow 10～20% and suitable adjuvant.
4, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease of claim 1～3, it is characterized in that: the Radix Salviae Miltiorrhizae total phenolic acids in the described prescription can be the highly finished product of tanshinol extract, Radix Salviae Miltiorrhizae water extract, Radix Salviae Miltiorrhizae water extract-alcohol precipitation extract, Radix Salviae Miltiorrhizae semi-bionic extraction thing, red sage root super critical extract or above each extract; Radix Astragali Mongolici total polysaccharide, total saponins can be the highly finished product of (+)-Astragenol extract, Radix Astragali water extract, Radix Astragali water extract-alcohol precipitation extract, Radix Astragali semi-bionic extraction thing, Radix Astragali supercritical extract or above each extract, and Carthamus yellow can be the highly finished product of Flos Carthami alcohol extract, Flos Carthami water extract, Flos Carthami water extract-alcohol precipitation extract, Flos Carthami semi-bionic extraction thing, Flos Carthami supercritical extract or above each extract.
5, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease of claim 1～4, it is characterized in that: described composite preparation be directly used in the injection of drug administration by injection, directly for the venous transfusion of intravenous drip, need be used for the concentrated solution for injection of intravenous drip and injectable sterile powder and aseptic block and tablet, capsule, granule, drop pill, pellet, pill, soft capsule, oral liquid, oral cavity disintegration tablet or the dispersible tablet that makes with freeze-drying or spray drying method after the dilution.
6, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 5, it is characterized in that: described composite preparation can make on the basis that in Radix Salviae Miltiorrhizae total phenolic acids and Radix Astragali Mongolici total polysaccharide, the total saponins and Flos Carthami flavochrome one or more is prepared into liposome or pro-liposome.
7, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: contain liposoluble ingredient, saponin component, polysaccharide composition and Flos Carthami flavochrome composition in the preparation, calculate by weight percentage, liposoluble ingredient content, saponin component content, polysaccharide component content and Carthamus yellow component content sum are not less than 50% of the total solid of deducting adjuvant amount and water quantities in the preparation in the preparation.
8, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 4, it is characterized in that: calculate according to percentage by weight, the content of liposoluble ingredient is not less than 50% in the Radix Salviae Miltiorrhizae total phenolic acids, the content of polysaccharide composition is not less than 50% in the Radix Astragali Mongolici total polysaccharide, and the content of saponin component is not less than 50% in the Radix Astragali total saponins.
9, as the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that:
A, described Carthamus yellow are preparations like this: get flos carthami, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Flos Carthami crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Carthamus yellow;
B, described Radix Salviae Miltiorrhizae total phenolic acids effective site are preparations like this: get red rooted salvia, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Salviae Miltiorrhizae crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Salviae Miltiorrhizae total phenolic acids effective site;
C, described Radix Astragali total saponins effective site are preparations like this: get Milkvetch Root, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate Radix Astragali crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Astragali total saponins effective site;
D, described Radix Astragali Mongolici total polysaccharide effective site are preparations like this: get Milkvetch Root, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate Radix Astragali crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Astragali Mongolici total polysaccharide effective site.
10, preparation of drug combination method according to any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: the Injectable sterile block of described compositions prepares like this: get Radix Salviae Miltiorrhizae total phenolic acids and Carthamus yellow, Radix Astragali Mongolici total polysaccharide, one or more of total saponins, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.0～7.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5% boiled coarse filtration 30 minutes, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-16 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2 hours approximately, keeps this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 10 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 9～11 hours, kept more than 35 ℃ dry 2.5 hours, gland, promptly.
11, according to the preparation of drug combination method of the described treatment cardiovascular and cerebrovascular disease of claim 6, it is characterized in that: the pro-liposome in the described preparation prepares like this: get one or more of Radix Salviae Miltiorrhizae total phenolic acids and Carthamus yellow, Radix Astragali Mongolici total polysaccharide, total saponins, add the phosphate buffer dissolving, add in the fused solution of fabaceous lecithin, cholesterol and 18-amine. mixing, stir supersound process, freezing, the dry powder that obtains sieves, promptly.
12, as the application of the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: described compositions is mainly used in the application in disease medicaments such as preparation treatment ischemia apoplexy, angina pectoris, cardiac insufficiency, apoplexy sequela, hepatorenal syndrome, heart and lung diseases, diabetes and complication thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115951 CN1961922A (en) | 2005-11-11 | 2005-11-11 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115951 CN1961922A (en) | 2005-11-11 | 2005-11-11 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1961922A true CN1961922A (en) | 2007-05-16 |
Family
ID=38081262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510115951 Pending CN1961922A (en) | 2005-11-11 | 2005-11-11 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1961922A (en) |
-
2005
- 2005-11-11 CN CN 200510115951 patent/CN1961922A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1961915A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1981800A (en) | Chinese-medicinal preparation for treating cardiovascular diseases, its production and use | |
| CN1961903A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961922A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961913A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961918A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961904A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961910A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961905A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961901A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961921A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN100998641A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease, preparing method and use thereof | |
| CN1961916A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961920A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961917A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN100998642A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease, preparing method and use thereof | |
| CN1961914A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961919A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN100998643A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease, and preparing method and use thereof | |
| CN100998600A (en) | Traditional Chinese medicine preparation for treating cardiovascular or cerebrovascular diseases, preparing method and use thereof | |
| CN1961902A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961909A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN100998622A (en) | Traditional Chinese medicine preparations for treating cardiovascular and cerebrovascular diseases the preparation method and use thereof | |
| CN1981801A (en) | Chinese-medicinal preparation for treating cardiovascular diseases, its production and use | |
| CN1961900A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |